Power3 Medical Products, Inc. Files for Patent on Diagnosis of Early Stage Parkinsons Disease

Mon. August 03, 2009; Posted: 07:00 AM
http://www.tradingmarkets.com/.site/...0News/2455943/

Woodlands, TX, Aug 03, 2009 (WORLD STOCK WIRE via COMTEX) -- TBIO | Quote | Chart | News | PowerRating -- Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced today that the Company has filed a patent for Diagnosis of Early Stage Parkinsons Disease: Abnormal: Blood Serum Concentrations of a Select Group of Protein Biomarkers.

Power3 Medical Products, Inc. filed a provisional patent on the diagnosis
of early stage Parkinsons disease: abnormal blood serum concentrations of a select group of protein biomarkers. This not only announces to the industry the progress of the Nuro-Pro-PD test for Parkinsons, in validation, utility, but that the importance of the Power3 protein biomarkers are statistically valid for use as a diagnostic test.

This work was done in conjunction with Transgenomic, Inc. license/collaboration agreement. The patent provides coverage of biomarkers and the computation/statistical methods used to discriminate the disease vs. the normal controls.

"Power3 Medical is continuing the portfolio of it intellectual property in Neurodegenerative diagnosis. We recently filed a patent on the ability of Power3's Nuro-Pro-PD test, using a series of abnormal blood serum biomarkers, to distinguish the early onset of Parkinson's disease", stated Dr. Ira L. Goldknopf, President and Chief Scientific Officer of Power3. "This patent is a break through declaration of new discoveries in this field."